zenocutuzumab
merus
['zenocutuzumab', 'merus']
 2022 updates: #zenocutuzumab has demonstrated encouraging activity &amp; a favorable tolerability profile across an array of nrg1 fusion-positive tumors in phase ii enrgy trial presented at the #asco 2022. learn more: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry